NewsRoom Articles - Page 59 of 214

WednesdayOct 04, 2023 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $1.33 Million from Registered Direct Offering to Boost Commercial Development

Scinai Immunotherapeutics recently announced the closing of a registered direct offering, raising $1.33 million in gross proceeds The company intends to use the net proceed from the offering for, among others, research and development On its R&D agenda is the development and commercialization of novel innovative NanoAbs targeting a wide range of diseases with known and validated antibody drug targets This strategic approach is expected to shorten development timelines, reduce the budgetary requirements, and increase probability of drug approval The company has also expanded into the CDMO business to plug an existing gap in the market, raising recurring revenue as…

TuesdayOct 03, 2023 1:51 pm

TikTok Hit as Indonesia Announces e-Commerce Transaction Ban on Social Media

Indonesian authorities dealt a major blow to TikTok’s expansion plans after they announced a national ban on virtual transactions on social media platforms. The social media platform TikTok has been working to accelerate e-commerce transactions in Indonesia, its largest market in Southeast Asia, as it fields increased scrutiny in other markets. However, the country’s government seems to have pulled the rug out from under TikTok’s feet. According to the government, the ban on social media e-commerce transactions is meant to protect offline marketplaces and merchants from the predatory pricing models on social media platforms that often outprice and threaten small…

MondayOct 02, 2023 11:42 am

Novel Type of Immunotherapy Exhibits Efficacy Against Brain Tumors in Mouse Models

A multi-institutional team of researchers has developed a novel type of cellular immunotherapy that has proven its therapeutic effectiveness in mouse models. Comprised of a researcher from the German Cancer Research Center and a University Medical Center Mannheim physician, the team used NLGN4X-specific T cells to successfully kill brain tumor cells from mice. NLGN4X (Neuroligin4X) is a protein that is involved in protein formation, and it occurs in large amounts in glioblastoma tumor cells even though they are barely present in healthy brain tissue. Glioblastoma is a type of brain cancer that originates in the nerve cell astrocytes within the…

MondayOct 02, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Finalizes Rebrand to Reflect New Strategic Direction, Diversification

Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs Amir Reichman took over as CEO in March 2021 and together with the Board of Directors, began implementing a raft of changes aimed at redirecting the company’s focus and diversifying corporate risks Scinai is developing a pipeline of novel NanoAbs, with its development pipeline including NanoAbs for the treatment of…

FridaySep 29, 2023 2:50 pm

CDC Avails $262M to New Network Aimed at Responding to Future Disease Outbreaks

The Centers for Disease Control (CDC) will provide $262 million to fund the development of a new disease outbreak response network. Per the announcement, recipients will receive grants from the pool of more than $250 million to establish America’s first-ever response network in anticipation of future disease outbreaks. The grants will fund the development and implementation of new tools meant to detect and mitigate public health emergencies such as pandemics and disease outbreaks in the future. According to a statement from the CDC, it will distribute funds for the development of the Outbreak Analytics and Disease Modeling Network (OADMN) to…

FridaySep 29, 2023 11:15 am

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video: Progress Report on ASD and Hope for the Future

Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials In 2024, we're poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program With NDA approval, we anticipate the potential to…

FridaySep 29, 2023 9:00 am

Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment

by Elaine Mendonça On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8. The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of neurites. To truly understand the underlying mechanisms responsible for CNM-Au8’s neuroprotective function,…

ThursdaySep 28, 2023 2:21 pm

Eliminating Barriers Surrounding Solid Tumors Allows T Cells to Kill Cancerous Cells

A recent University of Pennsylvania study has found that getting rid of the barriers surrounding solid tumors allows T cells to kill cancer cells more effectively. The research indicates that it is possible to make immunotherapies more effective at treating solid tumors such as lung cancer and pancreatic cancer. Immunotherapy is a relatively new type of cancer treatment that involves “training” the immune system to make it more effective at identifying and killing cancerous cells in the body. However, while this treatment has proven to be relatively effective at treating blood cancers, immunotherapies rarely have an impact on solid cancers.…

ThursdaySep 28, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11% RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products…

ThursdaySep 28, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $1.33 Million from Registered Direct Offering to Boost Commercial Development

TikTok Hit as Indonesia Announces e-Commerce Transaction Ban on Social Media

Novel Type of Immunotherapy Exhibits Efficacy Against Brain Tumors in Mouse Models

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Finalizes Rebrand to Reflect New Strategic Direction, Diversification

CDC Avails $262M to New Network Aimed at Responding to Future Disease Outbreaks

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video: Progress Report on ASD and Hope for the Future

Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment

Eliminating Barriers Surrounding Solid Tumors Allows T Cells to Kill Cancerous Cells

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search